ClinicalTrials.gg
CompletedNCT00067262Updated Aug 4, 2006

An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents

A Phase 3 interventional study of Divalproex Sodium Extended-Release Tablets in Bipolar Disorder, sponsored by Abbott. Completed at 16 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2006-08-04.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing Valproic Acid in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Valproic Acid · Bipolar Disorder.

Enrollment
13th of 41
150 · median 58
Started
2003
with 6 others
Phase 3
11 of 41
none open now
Registered
4th of 41
by date
Lead sponsor
2 of 41
Abbott

Among the 41 studies testing Valproic Acid in Bipolar Disorder, this one is the 13th largest by enrollment, is one of 7 that started in 2003, is one of 11 in phase 3, and was the 4th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 41 studies testing Valproic Acid in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing Valproic Acid in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of Depakote ER (Divalproex Sodium Extended-Release Tablets) compared to placebo in the treatment of bipolar disorder, manic or mixed type in children and adolescents ages 10-17 years.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Bipolar Disorder Type 1 (manic or mixed type)
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current primary diagnosis of bipolar I disorder, mania or mixed type
  • Outpatient between 10 and 17 years of age
  • Young Mania Rating Scale score greater than or equal to 20 during screening/washout and at Day 1

Exclusion criteria

EXCLUSION CRITERIA

  • Axis I other than Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Panic Disorder; or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results
  • Current manic episode is drug-induced or secondary to a medical disorder (e.g., anti-depressants, hyperthyroidism)
  • Expected to require hospitalization for the current manic episode
  • Participation in psychotherapy that was started within the past 3 months, or if any significant changes are anticipated
  • Has taken atomoxetine or has taken allowed stimulant medication that has not been stable for at least 3 months prior to Day 1, or a dosage adjustment is expected during the study, or that may worsen mood symptoms
  • Unable to swallow tablets
  • Has received depot psychoactive medication within one inter-injection interval of Day 1
  • Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine, barbiturates, benzodiazepines or amphetamines
  • History of alcohol or substance dependence within past 3 mos. or substance abuse within past month
  • History of failed treatment on adequate Depakote (DR or ER) for a manic episode within past 12 months
  • Has taken Depakote (DR or ER) regularly for the current manic episode
  • Has serious violent, homicidal, or suicidal ideation
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants
06

What researchers measure

Primary outcomes

  1. Change from baseline to the final evaluation in Y-MRS score.

Secondary outcomes

  1. Vital signs

  2. Adverse events

07

Study locations

16 sites
  • Stanford University
    Stanford, California 94304, United States
  • Childrens National Medical Center
    Washington, District of Columbia 20010, United States
  • Altamonte Springs, Florida 32701, United States
  • Professional Clinical Research, Inc.
    Miami, Florida 33161, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Mountain West Clinical Trials
    Boise, Idaho 83704, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60031, United States
  • Cientifica Inc at Praire View, Inc.
    Newton, Kansas 67114, United States
  • Lexington, Kentucky 40509, United States
  • LSU - Health Science Center
    New Orleans, Louisiana 70112, United States
  • Brentwood Research Institute
    Shreveport, Louisiana 71101, United States
  • New Oakland Child/Adoles and Family Center
    Clinton Township, Michigan, United States
  • Mercy Health Research
    Chesterfield, Missouri 63017, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma, United States
  • University of Texas Medical Branch
    Galveston, Texas 77705, United States
  • University of Texas Medical Branch
    Houston, Texas 77058, United States
08

References and documents

Publications

  • Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, Wozniak P, Vigna NV, Abi-Saab W, Saltarelli M. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):519-532. doi: 10.1097/CHI.0b013e31819c55ec. PubMed 19325497 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00067262
Lead sponsor
Abbott
First posted
Aug 15, 2003
Start date
Mar 2003
Last update
Aug 4, 2006

Study contacts

Global Medical Information
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion